Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasm Metastasis 30Prostatic Neoplasms 18Breast Neoplasms 17Lung Neoplasms 16Glioblastoma 16Carcinoma, Non-Small-Cell Lung 15Colorectal Neoplasms 14Pancreatic Neoplasms 12Multiple Myeloma 12Glioma 12Carcinoma, Renal Cell 10Brain Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma, Follicular 9Astrocytoma 9Neoplasms 8Melanoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Lymphoma, B-Cell 6Gliosarcoma 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Carcinoma 6

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × Magnetic Resonance Spectroscopy × Clear all
NCT01143779 2022-01-04

FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled

Advanced Cancer

NCT00610493 2017-12-08

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

M.D. Anderson Cancer Center

Phase 1 Completed
193 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡